Table 5.
Relevant Parameters of the PCI Research in the AM-BM
| Cancer | Species | Monitoring intracranial tumor formation | Injection method | Cell line | Cell number/ volume (cells/µl) |
Irradiator | Irradiation time (days) | Dose/Fraction (Gy/F) |
Dose rate (Gy/min) |
Effect (vs control) |
Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Breast
Cancer |
6-8w Female nude mice |
MRI | ICA | MDA-MB-231-BR-HER2 | 1.75×105/100 | custom micro-irradiation system | 1 and 2 | 20/2 | 0.13±0.01 | Tumor volume ↓ Tumor number ↓ Non-proliferative cancer cells — (the iron label) |
78 |
|
Breast
Cancer |
3-5w Female SCID/Beige mice |
NA | TVI | MDA-IBC3 (HER2-neu-overexpressing) | 5×105/NA | NA | 2 (before cells were injected) 5, 21, or 42 |
4/1 | NA | The rates of brain metastasis↓ (5 days) |
57 |
|
Breast
Cancer |
3-5w Female immunocompromised SCID/Beige mice (Harlan, USA) |
IVIS | TVI | MDA-IBC3 | 5×105/200 | X-RAD 225Cx small-animal irradiator (PRECISION X-RAY, North Branford, CT, USA) | 2 (before tumor-cell injection) 5 days, 3 weeks, or 6 weeks |
4/1 | 3.2 | The rates of brain metastasis↓ (5 days) |
56 |
|
Breast
Cancer |
6-8 w Female BALB/c mice | MRI | ICA | 4T1‐BR5 | 2×104/100 | In‐house custom micro‐irradiation system (140 kVp, 50 kW) with on‐board image guidance | 7 (before cell delivery) | 10/1 | NA | Tumor volume and number ↑ | 51 |
| NSCLC | 6-8 w male BALB/c nude mice | IVIS | ICD | A549-F3 | 2×105/100 | Rad Source Technologies Inc., Suwanee, GA | 7 (before cell delivery) | 6/2 | NA | PCI activates microglia, reduces the localization ability of NSCLC brain metastasis cells | 134 |